摘要:
The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.
摘要:
The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.
摘要:
A compound of formula (I) the process of preparing compounds of formula (I), their pharmaceutical compositions, and the method of treating diseases associated with M3 muscarinic and/or S—HT4 serotoninergic receptors.
摘要:
The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1 represents a hydrogen atom or a (C1-C4)alkyl group, a —CO(C1-C4)alkyl group, a phenyl-(C1-C4)alkyl group or a —COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C1-C4)alkoxy group; R2 is a hydrogen atom or an —SO2(C1-C4)alkyl group, an —SO2phenyl-(C1-C4)alkyl group or an —SO2phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C1-C4)alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R3 represents a hydrogen or halogen atom, a (C1-C6)alkyl group, a (C1-C4)alkoxy group, a —COO(C1-C4)alkyl group, a —CO(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl groups, —NO2, —CN, —CONR4R5, —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R4 and R5 represent, independently, a hydrogen atom, a phenyl, a (C1-C4)alkyl group or a phenyl-(C1-C4)alkyl group or R4 and R5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.
摘要:
The present invention relates to a process for the manufacture of glass sheets, according to which molten glass is poured into a liquid support which is denser than the glass to form a glass strip. The glass strip is drawn and is accompanied in its movement using a continuous and flexible guiding element made of a solid material capable of adhering to the molten glass, the elements being brought into contact with the side edges of the strip. The product (P) of the value (s) of the speed of the strip and of the value (t) of its final thickness is less than 2.5.times.10.sup.-4 m.sup.2 s.sup.-1. The process makes it possible to obtain thin glass sheets exhibiting a constant thickness and a satisfactory optical quality.
摘要:
The present invention is directed to a compound of formula (I): wherein Ar1, Ar2, Ar3, R1 and T are as defined herein, its preparation, pharmaceutical composition and uses as orexin 2 receptor antagonist.
摘要:
Woven or nonwoven long fiber sheets filled with two precursors each constituting an intermediate stage in a process for the preparation of a vitreous ceramic composition by the sol-gel route by hydrolysis and polycondensation using alcoholates or analogous compounds as the starting materials, that is to say an interface precursor in the form of a gel rich in water and a matrix precursor in the form of discrete particles capable of sintering at relatively low temperature, are stacked; the fibrous structure is compressed in the direction of stacking and the whole is heat-treated in order to convert the two precursors into a continuous matrix.
摘要:
The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1 represents a hydrogen atom or a (C1-C4)alkyl group, a —CO(C1-C4)alkyl group, a phenyl-(C1-C4)alkyl group or a —COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C1-C4)alkoxy group; R2 is a hydrogen atom or an —SO2(C1-C4)alkyl group, an —SO2phenyl-(C1-C4)alkyl group or an —SO2phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C1-C4)alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R3 represents a hydrogen or halogen atom, a (C1-C6)alkyl group, a (C1-C4)alkoxy group, a —COO(C1-C4)alkyl group, a —CO(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl groups, —NO2, —CN, —CONR4R5, —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R4 and R5 represent, independently, a hydrogen atom, a phenyl, a (C1-C4)alkyl group or a phenyl-(C1-C4)alkyl group or R4 and R5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.
摘要:
A 1-amino-phthalazine derivative of general formula (I) wherein the substituents are as defined herein. Also disclosed are a method for preparing such compounds, intermediates for use in such method and medical treatments using the compounds of formula (I).
摘要:
This invention concerns a thermally stable glass composition, which comprises the following constituents in the following proportions by weight: ______________________________________ SiO.sub.2 45 to 68% Al.sub.2 O.sub.3 0 to 20% ZrO.sub.2 0 to 20% B.sub.2 O.sub.3 0 to 10% Na.sub.2 O 2 to 12% K.sub.2 O 3.5 to 9% CaO 1 to 13% MgO 0 to 8% ______________________________________ the sum of the contents of the oxides SiO.sub.2, Al.sub.2 O.sub.3 and ZrO.sub.2 remaining equal to or less than 70%, the sum of the oxides Al.sub.2 O.sub.3 and ZrO.sub.2 being equal to or greater than 2%, the sum of the alkaline oxides Na.sub.2 O and K.sub.2 O being equal to or greater than 8%, said composition comprising, if desired, the oxides BaO and/or SrO in proportions such that: 11%.ltoreq.MgO+CaO+BaO+SrO
摘要翻译:PCT No.PCT / FR95 / 01347 Sec。 371日期1996年12月13日第 102(e)日期1996年12月13日PCT提交1995年10月13日PCT公布。 公开号WO96 / 11887 日期1996年04月25日本发明涉及一种热稳定性玻璃组合物,其包含以下重量比的以下组分:SiO 2 45至68%Al 2 O 3 0至20%ZrO 2 0至20%-B 2 O 3 0至10% - Na2O 2〜12% - K2O 3.5〜9% - CaO 1〜13% - MgO 0〜8% - 氧化物SiO 2,Al 2 O 3和ZrO 2的含量之和等于或小于70% 氧化物Al 2 O 3和ZrO 2等于或大于2%,碱性氧化物Na 2 O和K 2 O的总和等于或大于8%,如果需要,所述组合物包含氧化物BaO和/或SrO,其比例使得 :11% = MgO + CaO + BaO + SrO <30%该玻璃组合物可用于生产用于发射屏幕或耐火玻璃板的基板。